Research Paper Volume 13, Issue 5 pp 6724—6739
MiR-506 exerts antineoplastic effects on osteosarcoma cells via inhibition of the Skp2 oncoprotein
- 1 Postdoctoral Research Center on Public Health and Preventive Medicine, Xinjiang Medical University, Xinjiang, China
- 2 Fifth Affiliated Hospital, Xinjiang Medical University, Xinjiang, China
- 3 Department of Orthopedics, Sixth Affiliated Hospital, Xinjiang Medical University, Xinjiang, China
- 4 Department of Maternal, Child and Adolescent Health, College of Public Health, Xinjiang Medical University, Xinjiang, China
- 5 Tumor Hospital Affiliated to Xinjiang Medical University, Xinjiang, China
- 6 Postdoctoral Research Center on Clinical Medicine, First Affiliated Hospital, Xinjiang Medical University, Xinjiang, China
Received: July 13, 2020 Accepted: October 11, 2020 Published: February 17, 2021https://doi.org/10.18632/aging.202530
How to Cite
Copyright: © 2021 Ding et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
S-phase kinase-associated protein 2 (Skp2) performs oncogenic functions in cancers; however, how Skp2 is regulated post-transcriptionally is elusive in osteosarcoma. Therefore, we determined whether miR-506 could directly target Skp2 in osteosarcoma to perform its tumor suppressive functions. Here, we found that miR-506 mimics suppressed cell viability, induced apoptosis, and attenuated migration and invasion in osteosarcoma cells. Moreover, upregulation of Skp2 accelerated cell viability and motility and rescued the tumor suppressive effect of miR-506 in osteosarcoma cells. Moreover, downregulation of Skp2 inhibited cell viability and decreased cell motility, which enhanced the antitumor activity induced by miR-506 mimic transfection in osteosarcoma cells. Our western blotting results implied that miR-506 inhibited Skp2 expression and subsequently upregulated Foxo1 and p57 in OS cells. In summary, miR-506 performs an anticancer activity via directly targeting Skp2 in osteosarcoma cells, indicating that inactivation of Skp2 by miR-506 might be an alternative strategy for treating osteosarcoma.